Early versus delayed autologous transplantation after immunomodulatory agents-based induction therapy in patients with newly diagnosed multiple myeloma

Cancer

Volumn 118, Issue 6, 2012, Pages 1585-1592

  Kumar, Shaji K ^a   Lacy, Martha Q ^a   Dispenzieri, Angela ^a   Buadi, Francis K ^a   Hayman, Suzanne R ^a   Dingli, David ^a   Gay, Francesca ^b   Sinha, Shirshendu ^a   Leung, Nelson ^a   Hogan, William ^a   Rajkumar, S Vincent ^a   Gertz, Morie A ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

delayed transplantation; lenalidomide; multiple myeloma; stem cell transplantation; survival; thalidomide

Indexed keywords

BETA 2 MICROGLOBULIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; GRANULOCYTE COLONY STIMULATING FACTOR; LACTATE DEHYDROGENASE; LENALIDOMIDE; MELPHALAN; THALIDOMIDE;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER GROWTH; CANCER RELAPSE; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE CONTROL; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG RESPONSE; DRUG TOLERABILITY; EARLY INTERVENTION; FEMALE; FOLLOW UP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; STEM CELL MOBILIZATION; SURVIVAL RATE; THERAPY DELAY; TREATMENT DURATION;

ADULT; AGED; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; SURVIVAL RATE; TRANSPLANTATION, AUTOLOGOUS;

EID: 84858001524     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26422     Document Type: Article

References (23)

1. Kumar SK, Mikhael JR, Buadi FK, et al. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. Mayo Clin Proc. 2009; 84: 1095-1110.
2. Kyle RA, Rajkumar SV,. Multiple myeloma. N Engl J Med. 2004; 351: 1860-1873.
3. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med. 1996; 335: 91-97. (Pubitemid 26240110)
4. Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003; 348: 1875-1883. (Pubitemid 36532313)
5. Kumar SK, Dingli D, Lacy MQ, et al. Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma: results from a matched pair analysis. Am J Hematol. 2008; 83: 614-617.
6. Fermand JP, Ravaud P, Chevret S, et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood. 1998; 92: 3131-3136. (Pubitemid 28492319)
7. Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR,; Eastern Cooperative Oncology Group. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2006; 24: 431-436. (Pubitemid 46630462)
8. Rajkumar SV, Jacobus S, Callander NS, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol. 2010; 11: 29-37.
9. Harousseau J-L, Avet-Loiseau H, Attal M, et al. High complete and very good partial response rates with bortezomib-dexamethasone as induction prior to ASCT in newly diagnosed patients with high-risk myeloma: results of the IFM2005-01 phase 3 trial. Blood (ASH Annual Meeting Abstracts). 2009; 114. Abstract 353.
10. Harousseau JL, Mathiot C, Attal M, et al. VELCADE/dexamethasone (Vel/D) versus VAD as Induction treatment prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (MM): updated results of the IFM 2005/01 trial [abstract]. Blood (ASH Annual Meeting Abstracts). 2007; 110. Abstract 450.
11. Cavo M, Tacchetti P, Patriarca F, et al. A phase III study of double autotransplantation incorporating bortezomib-thalidomide-dexamethasone (VTD) or thalidomide-dexamethasone (TD) for multiple myeloma: superior clinical outcomes with VTD compared to TD [abstract]. Blood (ASH Annual Meeting Abstracts). 2009; 114. Abstract 351.
12. Lacy MQ, Gertz MA, Dispenzieri A, et al. Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma. Mayo Clin Proc. 2007; 82: 1179-1184. (Pubitemid 47502875)
13. Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006; 20: 1467-1473. (Pubitemid 44264086)
14. Greipp PR, Kumar S,. Plasma cell labeling index. Methods Mol Med. 2005; 113: 25-35.
15. Fermand JP, Katsahian S, Divine M, et al. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol. 2005; 23: 9227-9233.
16. Barlogie B, Kyle RA, Anderson KC, et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol. 2006; 24: 929-936. (Pubitemid 46638847)
17. Blade J, Rosinol L, Sureda A, et al. High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. Blood. 2005; 106: 3755-3759. (Pubitemid 41739009)
18. Gertz MA, Kumar S, Lacy MQ, et al. Stem cell transplant in multiple myeloma: impact of response failure with thalidomide or lenalidomide induction. Blood. 2010; 115: 2348-2353.
19. Kumar S, Dispenzieri A, Lacy MQ, et al. Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia. 2007; 21: 2035-2042. (Pubitemid 47299979)
20. Breitkreutz I, Lokhorst HM, Raab MS, et al. Thalidomide in newly diagnosed multiple myeloma: influence of thalidomide treatment on peripheral blood stem cell collection yield. Leukemia. 2007; 21: 1294-1299. (Pubitemid 46831819)
21. Mark T, Stern J, Furst JR, et al. Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma. Biol Blood Marrow Transplant. 2008; 14: 795-798. (Pubitemid 351773154)
22. Kumar S, Giralt S, Stadtmauer EA, et al. Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens. Blood. 2009; 114: 1729-1735.
23. Vesole DH, Jacobus S, Rajkumar SV, et al. Lenalidomide plus low-dose dexamethasone (Ld): superior 1 and 2 year survival regardless of age compared to lenalidomide plus high-dose dexamethasone (LD) [abstract]. Blood (ASH Annual Meeting Abstracts). 2010; 116: Abstract 308.